Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza and COVID-19 combination B
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
Influenza and COVID-19 combination B is a combined modified RNA vaccine candidate developed by BioNTech SE and Pfizer. It is designed to provide protection against both influenza and SARS-CoV-2 by delivering mRNA that instructs the body's cells to produce antigens from both viruses, thereby triggering an immune response. This vaccine aims to simplify immunization practices by offering simultaneous protection against these two common respiratory diseases.
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on influenza and COVID-19 combination B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza and COVID-19 combination B.